Physician

Jonathan Michael Horbal, D.O. PLC

According to 2025 Medicare claims, Jonathan Horbal, D.O. PLC (NPI: 1538396239) practices allergy/immunology in the Midland, MI market, with the plurality of this provider's patient population coming from Midland, MI. This provider's primary affiliated billing organization is JONATHAN M HORBAL DO PLC (NPI: 1063827152; TIN: 382434929) and primary practice location at 48640-4712. Horbal is affiliated with the POM ACO (ACO ID: A1297) and Mosaic ACO (ACO ID: A5033), participating under the MSSP model.

Horbal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 349 traditional Medicare patients, billed 8,357 HCPCS/CPT codes, and received $75,900 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 2,490 prescription claims across 648 beneficiaries totaling $416,029 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 31 claims. Open Payments data shows 2 records totaling $28. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $250,691 to $75,900. In contrast, Part D prescription costs have risen steadily, from $118,649 to $416,029. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	648	22,549	$250,691
2016	730	23,666	$285,175
2017	778	23,893	$294,637
2018	855	25,054	$342,000
2019	766	15,082	$193,264
2020	775	22,299	$271,743
2021	634	17,583	$215,564
2022	578	20,095	$218,489
2023	434	12,050	$122,130
2024	349	8,357	$75,900

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	435	1,428	$118,649
2016	632	2,550	$196,605
2017	815	3,493	$287,904
2018	943	4,210	$330,013
2019	777	2,926	$340,904
2020	565	2,154	$294,862
2021	529	1,868	$232,929
2022	551	2,011	$228,778
2023	593	2,421	$387,939
2024	648	2,490	$416,029

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	13	$46
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	12	$26,648
2022	N/R	51	$64,635
2023	N/R	26	$39,101
2024	N/R	31	$41,924

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	301	394	$67
94726	Test to determine lung volumes using sensors	76	76	$42
94060	Test to measure expiratory airflow and volume changes before and after medication administration	76	76	$29
95115	Professional service for single injection of allergen	102	118	$8
95004	Test for allergy using allergenic extract	79	5,756	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	69	3,388	$67,248
Xolair	Omalizumab	26	728	$60,893
Breo Ellipta	Fluticasone/Vilanterol	35	1,980	$24,816
Spiriva Respimat	Tiotropium Bromide	11	930	$13,423
Qvar Redihaler	Beclomethasone Dipropionate	29	2,160	$12,329

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	11	$35,331
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	20	$6,593

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$28	Takeda Pharmaceuticals U.S.A., Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jonathan Michael Horbal, D.O. PLC?

Tedicare shows public-source Medicare data for Jonathan Michael Horbal, D.O. PLC (NPI 1538396239), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jonathan Michael Horbal, D.O. PLC have ACO affiliation data?

Jonathan Michael Horbal, D.O. PLC is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297) and Mosaic ACO (MSSP, ACO ID A5033).

What billing organization is linked to Jonathan Michael Horbal, D.O. PLC?

Jonathan Michael Horbal, D.O. PLC is linked to JONATHAN M HORBAL DO PLC (billing NPI 1063827152) in the available physician profile data.

Does Jonathan Michael Horbal, D.O. PLC have Open Payments data?

Jonathan Michael Horbal, D.O. PLC has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.